KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Shares Outstanding (Weighted Average) (2016 - 2025)

Moderna (MRNA) has disclosed Shares Outstanding (Weighted Average) for 10 consecutive years, with $389.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.3% to $389.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $389.0 million through Dec 2025, up 1.3% year-over-year, with the annual reading at $389.0 million for FY2025, 1.3% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $389.0 million at Moderna, roughly flat from $388.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $404.0 million in Q3 2021, with the low at $381.0 million in Q3 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $390.6 million, with a median of $388.0 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 13.31% in 2021, then dropped 3.98% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $403.0 million in 2021, then dropped by 2.23% to $394.0 million in 2022, then dropped by 3.05% to $382.0 million in 2023, then rose by 0.52% to $384.0 million in 2024, then grew by 1.3% to $389.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $389.0 million, $388.0 million, and $388.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.